Webinar: Bringing the Western Blot into the 21st Century with Automated Simple Western - A Customer’s Perspective

The Western blot remains ubiquitous despite many challenges, including poor quantitation, high variability, and large sample consumption, time, and labor requirements. Simple Western™ platforms (developed by ProteinSimple, a Bio‑Techne brand) use capillary electrophoresis to automate protein separation and immunodetection of traditional Western blotting, eliminating many of the tedious, error-prone steps, providing quantitative results in as little as 3 hours.

Transferring Western blot assays to Simple Western is straightforward, and the same antibodies can often be used. Over 3000 antibodies from many different vendors have been validated for Simple Western. Cell Signaling Technology® (CST) provides high-quality research-use antibodies, employing rigorous validation to ensure the antibodies are highly specific, sensitive, and produce reproducible results. CST is the largest 3rd party supplier of antibodies validated for Simple Western, providing close to 25% of all antibodies validated so far.

In this Webinar, Dr. Chris LaBreck will share a customer’s perspective on the ease of transferring traditional western blotting assays that utilize high-quality antibodies from CST onto Simple Western’s Jess instrument and demonstrate the high performance of CST antibodies on Simple Western. With the automation and throughput provided by the Jess system, over 100 CST antibodies were screened in under two months as part of a pilot study with an 83% pass rate. CST and Bio‑Techne have an ongoing, long‑term partnership to continue validating antibodies on the Jess platform. An overview of Simple Western technology and its critical advantages will also be provided.